Effect of omalizumab on inflammatory markers in COVID-19: an exploratory analysis of the COVID-19 immunologic antiviral therapy with omalizumab (CIAO) trial.
Prosty C, Le M, Lu Y, Khoury L, Cormier M, Cheng MP, Fowler R, Murthy S, Tsang JL, Lejtenyi D, Ben-Shoshan M, Rahme E, Golchi S, Dendukuri N, Lee TC, Netchiporouk E.
Prosty C, et al. Among authors: lu y.
Front Med (Lausanne). 2024 Nov 19;11:1437322. doi: 10.3389/fmed.2024.1437322. eCollection 2024.
Front Med (Lausanne). 2024.
PMID: 39629239
Free PMC article.